MCL1 and breast cancer: Combined inhibition of BCL-2 and BCL-xL with ABT-263 had limited efficacy on breast cancer owing to high expression of MCL-1, while A-1210477 or VU661013 in combination ABT-263 has a synergistic effect [140, 141].